百利天恒：iza-bren又一适应症III期临床研究期中分析达双主要终点

Core Viewpoint - The company announced significant progress in the Phase III clinical trial of iza-bren for locally advanced or metastatic triple-negative breast cancer, with the independent data monitoring committee recommending early regulatory submission based on interim analysis results [1] Group 1: Clinical Trial Progress - The topline data indicates that iza-bren significantly extends progression-free survival (PFS) and overall survival (OS), achieving both primary endpoints [1] - This marks the third Phase III clinical trial where the dual antibody ADC has reached its primary endpoints [1] Group 2: Regulatory Status - As of now, iza-bren has seven indications included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and one indication by the U.S. Food and Drug Administration (FDA) [2] - Two indications for iza-bren, targeting locally advanced or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, have had their New Drug Applications (NDA) accepted by the NMPA and are in the priority review process [2] Group 3: Development and Market Considerations - The company emphasizes that drug registration requires completion of relevant clinical trials and approval from the NMPA before market launch, highlighting the lengthy and complex nature of the drug development process [2] - The company will actively promote the aforementioned research projects and comply with information disclosure obligations regarding project progress [2]